Abstract
The management of invasive aspergillosis in patients with hematological malignancies remains controversial. A major problem is how to manage patients who had invasive aspergillosis during remission induction and consolidation therapy and then undergo SCT. Indeed in these patients the mortality rate related to invasive aspergillosis recurrence remains unacceptably high. We report two cases of patients who underwent remission induction for AML, developed invasive aspergillosis during antifungal prophylaxis with itraconazole, failed amphotericin B deoxycholate and liposomal amphotericin B treatment, were successfully treated with voriconazole and eventually underwent SCT with voriconazole prophylaxis without reactivation of invasive aspergillosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Denning DW . Invasive aspergillosis Clin Infect Dis 1998 26: 781 805
Bow EJ, Loewen R, Cheang MS, Schacter B . Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen Clin Infect Dis 1995 21: 361 369
Maertens J, Verhaegen J, Lagrou K et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation Blood 2001 97: 1604 1610
Caillot D, Casanovas O, Bernard A et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computer tomographic scan and surgery J Clin Oncol 1997 15: 139 147
Pagano L, Girmenia C, Mele L et al. Infections caused by filamentous fungi in patients with hematological malignancies. A report of 391 cases by GIMEMA Infection Program Haematologica 2001 86: 862 870
Denning DW . Therapeutic outcome in invasive aspergillosis Clin Infect Dis 1996 23: 608 615
Robertson MJ, Larson RA . Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy Am J Med 1988 84: 233 239
Karp JE, Burch PA, Merz WG . An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis Am J Med 1988 85: 203 206
Nosari A, Cantoni S, Muti G et al. Itraconazole in leukemic patients with invasive aspergillosis: impact on intensive chemotherapy completion Eur J Haematol 1994 53: 183 185
Nosari A, Oreste P, Cairoli R et al. Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion Am J Hematol 2001 68: 231 236
Mele L, Pagano L, Equitani F, Leone G . Case reports. Secondary prophylaxis with liposomal amphotericin B after invasive aspergillosis following treatment for haematological malignancy Mycoses 2001 44: 201 203
Offner F, Cordonnier C, Ljungman P et al. Impact of previous aspergillosis on outcome of bone marrow transplantation Clin Infect Dis 1998 26: 1098 1103
Kappe R . Antifungal activity of the new azole UK – 109,496 (voriconazole) Mycoses 1999 42: (Suppl. 2) 83 86
Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis 2002 34: 563 571
Herbrecht R, Dennings DW, Patterson T et al. Open, randomized comparison of voriconazole (VRC) and amphotericin B (AmB) followed by other licensed antifungal therapy (OLAT) for primary therapy of invasive aspergillosis (IA) 41st ICAAC abstracts, Chichago, Illinois 22–25 September 2001 378 (Abstr. J-680)
Martino R, Lopez R, Sureda A et al. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature Haematologica 1997 82: 297 304
Richard C, Romon I, Baro J et al. Invasive pulmonary aspergilosis prior to BMT in acute leukemia patients does not predict a poor outcome Bone Marrow Transplant 1993 12: 237 241
Hoover M, Morgan ER, Kletzel M . Prior fungal infection is not a contraindication to bone marrow transplant in patients with acute leukemia Med Pediat Oncol 1997 28: 268 273
Sevilla J, Hernandez-Maraver D, Aguado MJ et al. Autologous peripheral blood stem cell transplant in patients previously diagnosed with invasive aspergillosis Ann Hematol 2001 80: 456 459
Michailov G, Laporte JP, Lesage S et al. Autologous bone marrow transplantation is feasible in patients with a prior history of invasive pulmonary aspergillosis Bone Marrow Transplant 1996 17: 569 572
Cowie F, Meller ST, Cushing P, Pinkerton R . Chemoprophylaxis for pulmonary aspergillosis during intensive chemotherapy Arch Dis Childhood 1994 70: 136 138
Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus Clin Infect Dis 2002 34: 7 14
Golstein JA, Blaisdell J . Genetic tests which identify the principle defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism Meth Enzymol 1996 272: 210 218
Acknowledgements
Voriconazole was supplied as compassionate treatment by Pfizer Central Research, Sandwich, UK.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mattei, D., Mordini, N., Lo Nigro, C. et al. Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation. Bone Marrow Transplant 30, 967–970 (2002). https://doi.org/10.1038/sj.bmt.1703763
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703763
Keywords
This article is cited by
-
Successful treatment of cerebral aspergillosis: case report of a patient with T-cell large granular lymphocytic leukemia (T-LGL)
BMC Infectious Diseases (2017)
-
Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients
Bone Marrow Transplantation (2004)
-
Histological examination of an eye with endogenous Aspergillus endophthalmitis treated with oral voriconazole: a case report
Graefe's Archive for Clinical and Experimental Ophthalmology (2004)